BTIG Research reaffirmed their buy rating on shares of Evolent Health (NYSE:EVH – Free Report) in a report released on Tuesday morning,Benzinga reports. Stephens reiterated an “equal weight” rating and set a $9.00 price objective on shares of Evolent Health in a research report on Wednesday, September 24th. Get Evolent Health alerts:Check Out Our Latest Stock Report on Evolent HealthEvolent Health Stock PerformanceNYSE:EVH opened at $7.87 on Tuesday. Evolent Health Company Profile(Get Free Report)Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. Further ReadingReceive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.